January 19, 2021
In the phase 2 JACCRO GC-07 trial, patients with stage III gastric cancer who received the combination of S-1 and docetaxel in the adjuvant setting had a 29% reduction in the risk of relapse.
January 16, 2021
In the frontline setting of FGFR2b-positive advanced gastric or gastroesophageal junction adenocarcinoma, the combination of bemarituzumab combined with mFOLFOX6 achieved a 56% reduction in the risk of disease progression or death compared with placebo.
January 15, 2021
Daniel Catenacci, MD, reviews the case of a 71-year-old man with gastric cancer.
December 01, 2020
Bassel El-Rayes, MD, reviews the case of a 66-year old man with gastric carcinoma and discusses the disease from diagnosis to unmet needs.
October 28, 2020
The FDA granted a Priority Review designation to the supplemental Biologics License Application for trastuzumab deruxtecan as treatment of patients with HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma.
October 24, 2020
Yelena Y. Janjigian, MD, discusses the differences between biomarker testing at academic centers versus community centers for patients with gastric cancer.
October 05, 2020
In an interview with Targeted Oncology following a virtual presentation for the ISGIO 2020, Yelena Janjigian, MD, provided an overview of the role of HER2-targeted therapies in advanced gastric cancer. She also explained the importance of biomarker testing in this space.
September 24, 2020
The FDA has granted a Fast Track designation to DKN-01 for the treatment of patients with gastric and gastroesophageal junction adenocarcinoma whose tumors express the protein DKK1, following disease progression on or after prior treatment with fluoropyrimidine- and platinum-containing chemotherapy and, if appropriate, human epidermal receptor growth factor/neu-targeted therapy.
September 21, 2020
In the phase 3 ATTRACTION-4 study, nivolumab added to chemotherapy led to a statistically significant improvement in progression-free survival and induced higher overall response rates in patients with previously untreated advanced or recurrent gastric and gastroesophageal junction cancer, according to results presented during the 2020 ESMO Virtual Congress.
August 11, 2020
Overall survival and progression-free survival were improved with nivolumab plus ipilimumab and chemotherapy compared with chemotherapy alone as frontline treatment of patients with metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma.